BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld Asia
Home
» Cellectis-Cellartis Join Forces, Focus on Personalized Medicine
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cellectis-Cellartis Join Forces, Focus on Personalized Medicine
Nov. 9, 2011
By
Nuala Moran
No Comments
LONDON – Cellectis SA has completed the acquisition of Europe's leading private stem cell company, the Swedish/British Cellartis AB, owner of 30 proprietary stem cell lines, in a cash and shares deal valued at €30 million (US$41.4million).
BioWorld Asia